Form 4: AbbVie COO Sells Shares for Tax Obligations

AbbVie's EVP and Chief Operations Officer, Azita Saleki-Gerhardt, reported a sale of 16,309 common shares to cover tax liabilities at a price of $232.08 per share.

Summary

• Azita Saleki-Gerhardt, EVP, Chief Operations Officer of AbbVie Inc. (ABBV), reported a transaction involving company common stock.
• On February 27, 2026, 16,309 shares of AbbVie common stock were disposed of at a price of $232.08 per share.
• The transaction code "F" indicates the disposition was for the payment of tax liability by delivering or withholding securities incident to the receipt, exercise, or vesting of a security.
• Following this transaction, Ms. Saleki-Gerhardt directly owns 197,794 shares of common stock.
• Additionally, 2,706 shares are held indirectly in an AbbVie Savings program, and 3,873 shares are held indirectly by her spouse, for which beneficial ownership is disclaimed.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction for tax purposes by an executive, which does not typically signal a change in company fundamentals or management's confidence.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled, non-discretionary sale.
• The sale was specifically for tax liability, which is a routine event for executives receiving equity compensation.

Negatives

• No specific negative points are identified from this routine tax-related share disposition.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as sales for tax purposes by executives, are common across the pharmaceutical industry. These transactions typically do not reflect a change in management's outlook on the company's prospects but rather a standard part of executive compensation and tax planning. Competitors like Pfizer or Merck also frequently report similar Form 4 filings for their executives.

Comparison to Industry Standards

• This transaction is a standard tax-related disposition, common among executives in large pharmaceutical companies.
• For example, executives at companies such as Johnson & Johnson or Bristol Myers Squibb frequently execute similar 'F' code transactions to cover tax liabilities arising from vesting equity awards.
• The volume of shares sold (16,309) is not unusually large for an EVP at a company of AbbVie's size, nor is the price ($232.08) indicative of any unusual market conditions specific to this transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, tax-related sale by an executive and not a discretionary sale indicating a change in sentiment.
• Employees: No direct impact.
• Management: Reflects standard executive compensation practices and tax planning.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary sale of shares by an executive to cover tax obligations, executed under a 10b5-1 plan. Such transactions are common and generally do not provide new fundamental information about the company's performance or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

AbbVie, ABBV, Form 4, Insider Trading, Executive Compensation, Share Sale, Tax Liability, Azita Saleki-Gerhardt, Chief Operations Officer, 10b5-1 Plan